Condition: HPV-Related Cervical Carcinoma · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Sponsor: Theravectys S.A.
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: * Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type * either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.
This description comes directly from the study's public registry record.
Daniel Loera · 713-256-8202 · dloera@oncobay.com
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists (from Sarah Canon research Institute) | Orlando, Florida, United States | Recruiting |
| Tampa General Hospital | Tampa, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Oklahoma Cancer Specialists and Research Institute, LLC | Tulsa, Oklahoma, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06319963